[{"bbox": [92, 101, 368, 132], "category": "Page-header", "text": "Q-Line Biotech Limited"}, {"bbox": [92, 167, 1557, 503], "category": "Table", "text": "<table><tr><td>Increase in Short Term Borrowings</td><td></td><td>2,072.10</td><td>247.55</td><td>2,431.45</td></tr><tr><td>Increase in Long Term Borrowings</td><td></td><td>4,731.88</td><td>2,078.61</td><td>588.47</td></tr><tr><td>Finance Cost including borrowing cost capitalize</td><td></td><td>(1,470.00)</td><td>(627.52)</td><td>(379.60)</td></tr><tr><td><strong>Net cash flow from financing activities</strong></td><td><strong>C</strong></td><td><strong>5,333.98</strong></td><td><strong>1,698.62</strong></td><td><strong>2,640.34</strong></td></tr><tr><td>Net Increase/(Decrease) In Cash & Cash Equivalents</td><td>(A+B+C)</td><td>(707.47)</td><td>(5,188.09)</td><td>2,505.82</td></tr><tr><td>Cash and Cash equivalents at the beginning of the year</td><td></td><td>1,971.43</td><td>7,159.53</td><td>4,653.71</td></tr><tr><td>Cash and Cash equivalents at the end of the year</td><td></td><td>1,263.95</td><td>1,971.43</td><td>7,159.53</td></tr></table>"}, {"bbox": [92, 532, 1557, 736], "category": "Table", "text": "<table><thead><tr><th>Notes :-</th><th></th><th>31-03-2025</th><th>31-03-2024</th><th>31-03-2023</th></tr></thead><tbody><tr><td>1.</td><td>Component of Cash and Cash equivalents</td><td></td><td></td><td></td></tr><tr><td></td><td>Cash on hand</td><td>43.03</td><td>88.34</td><td>99.28</td></tr><tr><td></td><td>Balance With banks</td><td>36.59</td><td>25.84</td><td>6,237.41</td></tr><tr><td></td><td>Other Bank Balance (As per AS -3 )</td><td>1,184.33</td><td>1,857.24</td><td>822.83</td></tr><tr><td></td><td><strong>Total</strong></td><td><strong>1,263.95</strong></td><td><strong>1,971.43</strong></td><td><strong>7,159.53</strong></td></tr></tbody></table>"}, {"bbox": [92, 769, 1564, 866], "category": "Text", "text": "2. Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, financing and investing activities of the company are segregated."}, {"bbox": [92, 897, 1564, 962], "category": "Text", "text": "The accompanying summary of significant accounting policies, restated notes to accounts and notes on adjustments for restated standalone financial Statement (Annexure IV & V, Annexure X to AC) are an integral part of this statement."}, {"bbox": [92, 1026, 604, 1150], "category": "Text", "text": "As per our consolidated report of even date\nFor R K Jagetiya & Co\nChartered Accountants\nFRN 146264W"}, {"bbox": [892, 1090, 1410, 1153], "category": "Text", "text": "FOR AND ON BEHALF OF THE BOARD\nQ- Line Biotech Limited"}, {"bbox": [690, 1185, 1116, 1279], "category": "Text", "text": "Saurabh Garg\nManaging Director & CHAIRMAN\nDIN: 02891621"}, {"bbox": [1291, 1185, 1548, 1279], "category": "Text", "text": "Amita Garg\nWhole-Time Director\nDIN: 02891610"}, {"bbox": [92, 1345, 479, 1533], "category": "Text", "text": "(CA Ravi K Jagetiya)\nM. No. 134691\nProprietor\nDate: 24th September, 2025\nPlace: Mumbai\nUDIN:- 25134691BMGTLA9821"}, {"bbox": [690, 1345, 1020, 1533], "category": "Text", "text": "Akhand Pratap Singh\nCompany Secretary\nPAN: CFRPS7649R\nDate: 24th September, 2025\nPlace: Lucknow"}, {"bbox": [1191, 1345, 1468, 1438], "category": "Text", "text": "Meenal Gupta\nChief Financial Officer\nPAN -:ABHPG6642E"}, {"bbox": [804, 2170, 848, 2197], "category": "Page-footer", "text": "187"}]